Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessing The Efficacy Of Combination Of Chemotherapy Plus Herceptin For Preventing Recurrence With ER Positive/HER2 Positive Breast Cancer

Next Previous
Search
Trial Profile

Assessing The Efficacy Of Combination Of Chemotherapy Plus Herceptin For Preventing Recurrence With ER Positive/HER2 Positive Breast Cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Trastuzumab (Primary) ; Letrozole
  • Indications Breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Jan 2020 New trial record
    • 14 Dec 2019 Results (N=32), of cohort A assessing the neo-adjuvant clinical response in post-menopausal women with ER positive/HER2 positive breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top